Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG19

—

61999de6-2f34-5b4f-ab66-03d7745d3633

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PROTEIN_SECRETION+0.467
  • INFLAMMATORY_RESPONSE+0.432
  • ANDROGEN_RESPONSE+0.415
  • TNFA_SIGNALING_VIA_NFKB+0.410
  • ALLOGRAFT_REJECTION+0.403
  • IL6_JAK_STAT3_SIGNALING+0.394
  • TGF_BETA_SIGNALING+0.338
  • IL2_STAT5_SIGNALING+0.333
  • INTERFERON_GAMMA_RESPONSE+0.331
  • KRAS_SIGNALING_UP+0.331

Top 10 suppressed

  • MYC_TARGETS_V2-0.327
  • OXIDATIVE_PHOSPHORYLATION-0.248
  • DNA_REPAIR-0.237
  • WNT_BETA_CATENIN_SIGNALING-0.235
  • E2F_TARGETS-0.139
  • G2M_CHECKPOINT-0.096
  • NOTCH_SIGNALING-0.079
  • KRAS_SIGNALING_DN-0.039
  • MYOGENESIS-0.023
  • ADIPOGENESIS-0.015

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1MNG1172
mng-umap@100
——0.891
2BS_QRNSKFMS
brain-umap@2
pilocytic astrocytoma—0.852
3MNG1215
mng-umap@100
——0.849
4MDT-AP-0173
medullo-epn-umap@date-based
MedMedulloblastoma0.844
5SRR8518261
breast-umap@18
—C0.840
6BS_WRHDP7WF
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.833
7BS_V72GX2AZ
brain-umap@2
low-grade glioma—0.829
8BS_593HEWBF
brain-umap@2
Ganglioglioma—0.823
9MDT-AP-2910
medullo-epn-umap@date-based
MedMedulloblastoma0.822
10BS_014EVM2D
brain-umap@2
low-grade glioma—0.821

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 39 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PROTEIN_SECRETION0.467Remibrutinib— uncovered
INFLAMMATORY_RESPONSE0.432Idelalisib— uncovered
ANDROGEN_RESPONSE0.415Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.410Inavolisib— uncovered
ALLOGRAFT_REJECTION0.403Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.394Inavolisib— uncovered
TGF_BETA_SIGNALING0.338Inavolisib— uncovered
IL2_STAT5_SIGNALING0.333Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.331Idelalisib— uncovered
KRAS_SIGNALING_UP0.331Inavolisib— uncovered
APICAL_SURFACE0.316Temsirolimus— uncovered
APOPTOSIS0.313Idelalisib— uncovered
COMPLEMENT0.311Inavolisib— uncovered
MTORC1_SIGNALING0.310Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.291Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.274Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.272Cobimetinib— uncovered
ESTROGEN_RESPONSE_EARLY0.266Inavolisib— uncovered
PEROXISOME0.262Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.260Inavolisib— uncovered